Indivior Pharmaceuticals Inc

NASDAQ:INDV

Drug Manufacturers - Specialty & Generic

Healthcare
$36.28 +0.69%

+$0.26 today

Market cap
$4.53B
Beta
1.17
P/E (TTM)
19.1
EPS (TTM)
$2.00
52W Low $13.45High $41.00

Volume 3.65M

Average 2.08M

INDV Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Indivior Pharmaceuticals IncNASDAQ: INDV

Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026

Depreciation & amortization declines year over year

Q2 FY2026 depreciation & amortization of $3M fell 40.0% year over year, behind the -26.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 25.0% from the prior quarter. Over 3 fiscal years it compounded at +7.7% a year.

Context

  • Depreciation & amortization amounted to 1.6% of revenue in FY2025, down 0.7 pp from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -40.0% toward the trailing-twelve-month pace of -26.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$3M-25.0% QoQ
Last fiscal yearDec 2025
$20M-28.6% YoY
LTMJun 2026
$17M-26.1% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-40.0%——
1 year-28.6%——
3-year CAGR+7.7%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
20M USD
Year-over-year change
-28.6%
4-year CAGR
-2.4%

Depreciation & Amortization vs competitors

How INDV compares with its peers on the latest reported figures

  • INDV's LTM Jun 2026 depreciation & amortization of $17M is the smallest of the 4 companies compared; the peer median is $101.71M.
  • Its year-over-year change of -26.1% is the lowest of 4, against a peer median of +26.1%.
  • Depreciation & amortization amounts to 1.3% of revenue for INDV, versus a peer median of 12.2%.
INDV Competitors Peer median
Depreciation & Amortization for INDV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
COLLCollegium Pharmaceutical, Inc.LTM Mar 2026$227.86M +19.7%+16.7%28.6%
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026$101.71M +26.1%+2.3%12.2%
ALKSAlkermes plcLTM Sep 2026$80.71M +167.6%-29.6%4.6%
INDVIndivior Pharmaceuticals IncLTM Jun 2026$17M -26.1%+7.7%1.3%
Peer median (excluding INDV) $101.71M+26.1%+2.3%12.2%

Competitors are the stored peer set for INDV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income213M(44M)(126M)7M210M
Depreciation & Amortization22M16M15M28M20M
Deferred Income Tax00(64M)7M(46M)
Stock-Based Compensation11M16M21M24M26M
Change in Working Capital173M118M(297M)(46M)(257M)
Accounts Receivables(25M)(21M)(33M)(1M)3M
Inventory(3M)(30M)(6M)(43M)18M
Accounts Payables00000
Other Working Capital201M169M(258M)(2M)(278M)
Other Non-Cash Items(66M)(110M)151M16M20M
Operating Cash Flow353M(4M)(300M)36M(27M)
Capital Expenditures(34M)(5M)(53M)(31M)(67M)
Acquisitions (Net)00(129M)00
Purchases of Investments0(245M)(45M)(17M)(20M)
Sales of Investments027M129M117M20M
Other Investing Activities(10M)1M(42M)(2M)0
Investing Cash Flow(14M)(222M)(95M)69M(66M)
Debt Repayment14M(3M)(12M)92M(17M)
Common Stock Issued1M(8M)(19M)(19M)(3M)
Common Stock Repurchased(101M)(90M)(33M)(173M)(11M)
Dividends Paid00000
Other Financing Activities(8M)00(2M)1M
Financing Cash Flow(94M)(101M)(64M)(102M)(30M)
Effect of Forex Changes(1M)(1M)1M0(1M)
Net Change in Cash244M(328M)(458M)3M(124M)
Free Cash Flow319M(9M)(353M)5M(94M)

Indivior Pharmaceuticals Inc

NASDAQ:INDV

Intrinsic Alpha fair value

Locked

Current Price

$36.28

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.